Trials / Completed
CompletedNCT00161850
FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 Years
Follow-up Study to Investigate the Safety and Immunogenicity of a Third Vaccination With Three Different Antigen Concentrations of FSME IMMUN NEW in Children Aged 1 to 6 Years
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 615 (planned)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 1 Year – 6 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate the safety and immunogenicity of the third vaccination with one of three different concentrations of a TBE vaccine in all subjects who completed two vaccinations in one of the three treatment groups of Baxter study 199 (a dose-finding study to investigate the safety and immunogenicity of two vaccinations with FSME IMMUN NEW in healthy subjects aged 1 to 6 years).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Tick-Borne Encephalitis (TBE) Vaccine (Inactivated) |
Timeline
- Start date
- 2002-02-01
- Completion
- 2002-08-01
- First posted
- 2005-09-13
- Last updated
- 2015-05-21
Locations
25 sites across 2 countries: Austria, Germany
Source: ClinicalTrials.gov record NCT00161850. Inclusion in this directory is not an endorsement.